These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

47 related articles for article (PubMed ID: 15201455)

  • 1. Monitoring aggregate formation in organotypic slice cultures from transgenic mice.
    Smith DL; Bates GP
    Methods Mol Biol; 2004; 277():161-71. PubMed ID: 15201455
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tissue transglutaminase contributes to disease progression in the R6/2 Huntington's disease mouse model via aggregate-independent mechanisms.
    Bailey CD; Johnson GV
    J Neurochem; 2005 Jan; 92(1):83-92. PubMed ID: 15606898
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Time-lapse analysis of aggregate formation in an inducible PC12 cell model of Huntington's disease reveals time-dependent aggregate formation that transiently delays cell death.
    Gong B; Lim MC; Wanderer J; Wyttenbach A; Morton AJ
    Brain Res Bull; 2008 Jan; 75(1):146-57. PubMed ID: 18158109
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Euploidy in somatic cells from R6/2 transgenic Huntington's disease mice.
    Petersén A; Stewénius Y; Björkqvist M; Gisselsson D
    BMC Cell Biol; 2005 Sep; 6():34. PubMed ID: 16159402
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DNA microarray analysis of striatal gene expression in symptomatic transgenic Huntington's mice (R6/2) reveals neuroinflammation and insulin associations.
    Crocker SF; Costain WJ; Robertson HA
    Brain Res; 2006 May; 1088(1):176-86. PubMed ID: 16626669
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sustained striatal ciliary neurotrophic factor expression negatively affects behavior and gene expression in normal and R6/1 mice.
    Denovan-Wright EM; Attis M; Rodriguez-Lebron E; Mandel RJ
    J Neurosci Res; 2008 Jun; 86(8):1748-57. PubMed ID: 18293418
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impaired glucose tolerance in the R6/1 transgenic mouse model of Huntington's disease.
    Josefsen K; Nielsen MD; Jørgensen KH; Bock T; Nørremølle A; Sørensen SA; Naver B; Hasholt L
    J Neuroendocrinol; 2008 Feb; 20(2):165-72. PubMed ID: 18034868
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hsp27 overexpression in the R6/2 mouse model of Huntington's disease: chronic neurodegeneration does not induce Hsp27 activation.
    Zourlidou A; Gidalevitz T; Kristiansen M; Landles C; Woodman B; Wells DJ; Latchman DS; de Belleroche J; Tabrizi SJ; Morimoto RI; Bates GP
    Hum Mol Genet; 2007 May; 16(9):1078-90. PubMed ID: 17360721
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The R6 lines of transgenic mice: a model for screening new therapies for Huntington's disease.
    Gil JM; Rego AC
    Brain Res Rev; 2009 Mar; 59(2):410-31. PubMed ID: 19118572
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CGS21680 attenuates symptoms of Huntington's disease in a transgenic mouse model.
    Chou SY; Lee YC; Chen HM; Chiang MC; Lai HL; Chang HH; Wu YC; Sun CN; Chien CL; Lin YS; Wang SC; Tung YY; Chang C; Chern Y
    J Neurochem; 2005 Apr; 93(2):310-20. PubMed ID: 15816854
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of CAG repeat length, HTT protein length and protein context on cerebral metabolism measured using magnetic resonance spectroscopy in transgenic mouse models of Huntington's disease.
    Jenkins BG; Andreassen OA; Dedeoglu A; Leavitt B; Hayden M; Borchelt D; Ross CA; Ferrante RJ; Beal MF
    J Neurochem; 2005 Oct; 95(2):553-62. PubMed ID: 16135087
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Global changes to the ubiquitin system in Huntington's disease.
    Bennett EJ; Shaler TA; Woodman B; Ryu KY; Zaitseva TS; Becker CH; Bates GP; Schulman H; Kopito RR
    Nature; 2007 Aug; 448(7154):704-8. PubMed ID: 17687326
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of polyglutamine aggregation in R6/2 HD brain slices-complex dose-response profiles.
    Smith DL; Portier R; Woodman B; Hockly E; Mahal A; Klunk WE; Li XJ; Wanker E; Murray KD; Bates GP
    Neurobiol Dis; 2001 Dec; 8(6):1017-26. PubMed ID: 11741397
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proteasome impairment does not contribute to pathogenesis in R6/2 Huntington's disease mice: exclusion of proteasome activator REGgamma as a therapeutic target.
    Bett JS; Goellner GM; Woodman B; Pratt G; Rechsteiner M; Bates GP
    Hum Mol Genet; 2006 Jan; 15(1):33-44. PubMed ID: 16311253
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Normal sensitivity to excitotoxicity in a transgenic Huntington's disease rat.
    Winkler C; Gil JM; Araújo IM; Riess O; Skripuletz T; von Hörsten S; Petersén A
    Brain Res Bull; 2006 Apr; 69(3):306-10. PubMed ID: 16564426
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Blood level of brain-derived neurotrophic factor mRNA is progressively reduced in rodent models of Huntington's disease: restoration by the neuroprotective compound CEP-1347.
    Conforti P; Ramos C; Apostol BL; Simmons DA; Nguyen HP; Riess O; Thompson LM; Zuccato C; Cattaneo E
    Mol Cell Neurosci; 2008 Sep; 39(1):1-7. PubMed ID: 18571429
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oxidative damage in Huntington's disease.
    Segovia J; Pérez-Severiano F
    Methods Mol Biol; 2004; 277():321-34. PubMed ID: 15201466
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Depletion of Complexin II does not affect disease progression in a mouse model of Huntington's disease (HD); support for role for complexin II in behavioural pathology in a mouse model of HD.
    Glynn D; Reim K; Brose N; Morton AJ
    Brain Res Bull; 2007 Apr; 72(2-3):108-20. PubMed ID: 17352934
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The A2A adenosine receptor rescues the urea cycle deficiency of Huntington's disease by enhancing the activity of the ubiquitin-proteasome system.
    Chiang MC; Chen HM; Lai HL; Chen HW; Chou SY; Chen CM; Tsai FJ; Chern Y
    Hum Mol Genet; 2009 Aug; 18(16):2929-42. PubMed ID: 19443488
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Opposite effects of the A2A receptor agonist CGS21680 in the striatum of Huntington's disease versus wild-type mice.
    Martire A; Calamandrei G; Felici F; Scattoni ML; Lastoria G; Domenici MR; Tebano MT; Popoli P
    Neurosci Lett; 2007 Apr; 417(1):78-83. PubMed ID: 17331645
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.